Navigation Links
Isis Reports Financial Results and Highlights for 2012
Date:2/28/2013

opportunities for significant near-term revenue from partnerships while we are also setting the stage for significant future revenue growth," said Elizabeth L. Hougen, chief financial officer of Isis. 

"In 2013, we are predicting another year of strong financial performance while continuing to advance our pipeline. Although we are planning to have more than a dozen drugs in later-stage clinical studies throughout the year, we are projecting only a slight increase in our 2013 spending compared to 2012. As such, we expect to end 2013 with a pro forma NOL in the mid $60 million range. We are also projecting to end the year with more than $325 million in cash. Our guidance is supported by our partnering successes in 2012. Because most drugs are not profitable in their first year of commercialization, and because it is too early in the year to predict the revenue trajectory of KYNAMRO, we are being conservative in our projections by not including KYNAMRO profit share revenue this year.  We are pleased with the significant investment Genzyme is making to ensure a successful KYNAMRO launch.  This investment should support strong revenue growth in the future.  We are fortunate to have Genzyme with its expertise in selling and marketing orphan drugs commercializing KYNAMRO and we look forward to providing updates throughout the year on KYNAMRO's commercial success," concluded Ms. Hougen.

Upcoming Key Milestones

  • Receive KYNAMRO marketing opinion from the European regulatory agency
  • Initiate a Phase 2/3 program of ISIS-SMNRx in infants with spinal muscular atrophy
  • Report clinical data on ISIS-SMNRx at the American Academy of Neurology meeting in March
  • Report clinical data on ISIS-CRPRx in patients with rheumatoid arthritis
  • Report clinical data on ISIS-APOCIIIRx in patients with high triglycerides
  • Financial Results
    All pro forma amounts refer
    '/>"/>

    SOURCE Isis Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

    Related medicine technology :

    1. NxStage Reports Record Fourth Quarter and Full-Year 2012 Financial Results
    2. Valeant Pharmaceuticals Reports 2012 Fourth Quarter Financial Results
    3. Mylan Reports a 23% Increase in Fourth Quarter 2012 Adjusted Diluted EPS to $0.65
    4. HeartWare International Reports Fourth Quarter 2012 Revenue Of $32.7 Million; Full Year 2012 Revenue Of $110.9 Million
    5. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2012 Financial Results
    6. Kewaunee Scientific Reports Improved Results for Third Quarter
    7. Jazz Pharmaceuticals Reports Full Year And Fourth Quarter 2012 Financial Results
    8. Questcor Reports Fourth Quarter and Full Year 2012 Results
    9. ResearchMoz: Global MRI Systems Market to 2018 - Technological Advancements, Increasing Number of Applications and Advent of MRI Compatible Pacemakers to Drive Future Growth - Market Research Reports
    10. United Therapeutics Corporation Reports 2012 Fourth Quarter and Annual Financial Results
    11. Halozyme Reports Fourth Quarter and Year End 2012 Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:3/26/2015)... , March 26, 2015 Cardiologists at Beaumont ... the Midwest,s first commercial implant of a device recently ... with non-valvular atrial fibrillation. The Watchman Left Atrial Appendage ... blood-thinning warfarin medication to reduce the risk of stroke. ... rhythm disorder affecting more than 5 million Americans. Twenty ...
    (Date:3/26/2015)... 2015 Over-the-counter healthcare costs can be ... a new survey of store brand over-the-counter products ... cold to diabetes, can offer significant savings for ... the Private Label Manufacturers Association, assembled a market ... those essential for treatment of pre-diabetes and diabetes. ...
    (Date:3/26/2015)... March 26, 2015 Zimmer Holdings, Inc. (NYSE ... ® Advanced Bearing Technology with Vitamin E by ... published earlier this month reported that, at 96 million ... Advanced Bearing Technology featuring Vitamin E grafted highly crosslinked ... wear rate reduction of 95 percent, with no cracking, ...
    Breaking Medicine Technology:Beaumont Hospital, Royal Oak among first to offer alternative to blood-thinning medications for atrial fibrillation 2Beaumont Hospital, Royal Oak among first to offer alternative to blood-thinning medications for atrial fibrillation 3Consumers can keep over-the-counter medicine affordable by using store brands 2Zimmer Announces New Testing Milestone For Vitamin E Advanced Bearing Technology 2Zimmer Announces New Testing Milestone For Vitamin E Advanced Bearing Technology 3
    ... SAN DIEGO, Aug. 4, 2011 Optimer Pharmaceuticals, Inc. (NASDAQ: ... for the quarter ended June 30, 2011. (Logo: ... for the second quarter of 2011 of $24.2 million, or ... as compared to a net loss for the second ...
    ... Dehaier Medical Systems Ltd. (Nasdaq: ... in the development, assembly, marketing and sale of medical ... that it will release financial results for the second ... Monday, August 15, 2011 before the start of trading ...
    Cached Medicine Technology:Optimer Pharmaceuticals Reports Second Quarter 2011 Financial Results 2Optimer Pharmaceuticals Reports Second Quarter 2011 Financial Results 3Optimer Pharmaceuticals Reports Second Quarter 2011 Financial Results 4Optimer Pharmaceuticals Reports Second Quarter 2011 Financial Results 5Dehaier Medical to Report Second Quarter 2011 Financial Results on August 15 2
    (Date:3/27/2015)... 2015 Ticket Down is a reputable source ... in Omaha, Nebraska on Friday, May 8th and Saturday, ... dates will be added in Omaha as Garth has done ... The Garth Brooks World Tour is continuing its run throughout ... Garth Brooks and Trisha Yearwood will bring their act to ...
    (Date:3/27/2015)... Michigan (PRWEB) March 27, 2015 ... LiveToBeSober.org, along with former Detroit Lions wide receiver ... luncheon and educational presentation on substance abuse, treatment ... Among those who attended were pastors, ministers and ... leaders and other distinguished guests. , “Our ‘Fighting ...
    (Date:3/27/2015)... According to Health Day , on March ... Syndrome (NAS) are causing alarm for Florida officials. Infants ... for a month of their lives- and can experience ... The condition is precipitated by drug use during pregnancy. ... employing medically assisted drug treatment) will also inflict NAS ...
    (Date:3/27/2015)... (PRWEB) March 27, 2015 GrassrootsHealth, an ... Protect Our Children (POC) NOW! vitamin D demonstration project ... University of South Carolina (MUSC), and will soon follow ... available at no cost to a minimum of 500 ... live within these two service areas. The project will ...
    (Date:3/27/2015)... (PRWEB) March 27, 2015 Operatic contenders ... of greatness on April 17th. The universally acclaimed baritone ... the 9th annual Opera Idol at The Merion in ... competition, which has drawn aspiring opera singers from around ... showcases some of the finest young talent in the ...
    Breaking Medicine News(10 mins):Health News:Cheap Garth Brooks Tickets for CenturyLink Center in Omaha: Ticket Down Slashes Garth Brooks Concert Tickets in Omaha, NE at the CenturyLink Center 2Health News:Cheap Garth Brooks Tickets for CenturyLink Center in Omaha: Ticket Down Slashes Garth Brooks Concert Tickets in Omaha, NE at the CenturyLink Center 3Health News:LiveToBeSober.org Hosts Conference on Substance Abuse Treatment and Recovery at Ford Field 2Health News:In Florida Only 10% of Pregnant Mothers Are Referred to Drug Rehab Despite Testing Positive for Narcotics 2Health News:GrassrootsHealth Moves Vitamin D into Practice with Pregnant Women 2Health News:GrassrootsHealth Moves Vitamin D into Practice with Pregnant Women 3Health News:GrassrootsHealth Moves Vitamin D into Practice with Pregnant Women 4Health News:Opera Idol Competition At The Merion In Evanston 2
    ... chair to support efforts to address the rising ... in Maryland BALTIMORE, April 10 Richard H. ... General (2002-2006) and President of the non-profit Canyon ... elected Chairman of the Pharmaceutical Research and Manufacturers ...
    ... scientific article is cited by other articles is currently the ... measure: the number of unique downloads. , A recent ... that downloads are a good predictor of citations and ... in an editorial by Journal of Vision (JOV) ...
    ... 14-17, 2009, Underwriters Laboratories Inc.,s (UL) Primary Designated ... Manager Jola Wroblewska will present International Electrotechnical Committee ... (IECEE) CB Test Laboratories and National Certification Bodies ... promote common application of the guidelines prepared by ...
    ... April 10 Rheumatoid arthritis (RA) is a systemic ... defense system attacks the joints through the thin layer ... the joints. The most visible symptoms of RA are ... and feet. It can cause fatigue, fever, loss of ...
    ... eye physicians recommends , sport-specific eyewear to prevent devastating ... what started out as a routine basketball game his senior ... was a young basketball star who played years of hoops ... the eye by a teammate, Stephen ended up with a ...
    ... for skin appearance in 3 trials , , THURSDAY, April 9 ... to improve the healing of skin scars, according to three ... administered to their skin before wounding and again 24 hours ... the way through the skin of the upper inner arm ...
    Cached Medicine News:Health News:National Health Experts to Announce Creation of Bipartisan Coalition to Fight Maryland's Growing Burden of Chronic Disease Tuesday at Inner Harbor 2Health News:UL Medical Experts to Provide Instruction on Guidance for Risk Management in IEC 60601-1:2005 at IECEE Workshop 2Health News:Rheumatoid Arthritis Therapeutics in Taiwan 2Health News:Rheumatoid Arthritis Therapeutics in Taiwan 3Health News:Eye Protection is Essential for Texas Athletes 2Health News:Eye Protection is Essential for Texas Athletes 3Health News:Medication May Improve Scar Healing 2
    For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
    For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
    For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
    For the qualitative detection of cardiac troponin I (cTnl) in human whole blood and serum specimens...
    Medicine Products: